News Category Development Progress

HanchorBio Presents Two ASCO 2026 Abstracts Highlighting HCB101 Combination Activity and HCB301 First-in-Human Clinical Progress

HanchorBio announced updated clinical data for HCB101 and HCB301 presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Jun 01, 2026

HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study

HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens (NCT06771622).

May 18, 2026

HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances Key Preclinical Studies

HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.

May 11, 2026

HanchorBio Launches HCB101 Mechanism Collaboration Study with the Institute of Tsinghua University, Hebei

HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.

May 05, 2026

HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics

HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.

Apr 29, 2026

HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

Apr 22, 2026

HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

Apr 20, 2026

HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101

HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.

Apr 14, 2026

HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

Apr 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

Apr 03, 2026